Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma

L Max Almond, Alessandro Gronchi, Dirk Strauss, Mariam Jafri, Samuel Ford, Anant Desai

Research output: Contribution to journalReview article

Abstract

Extended surgery remains the mainstay of treatment in retroperitoneal sarcoma, although conflicting data exist on the benefit of neoadjuvant and adjuvant therapies, particularly with regard to tumour grade and histological type. Experience of radiotherapy and chemotherapy in extremity soft tissue sarcoma can inform treatment strategies, however these data cannot be universally extrapolated to the retroperitoneum where disease biology and anatomical considerations are different. The present review sets a historical context before discussing recent evidence and on-going multi-centre trials in retroperitoneal sarcoma. Promising data on histologically- and molecularly-targeted chemotherapy are discussed and the need for centralisation of retroperitoneal sarcoma services in order to facilitate large international collaborative trials is emphasised.

Original languageEnglish
Pages (from-to)571-579
Number of pages9
JournalEuropean Journal of Surgical Oncology
Volume44
Issue number5
DOIs
Publication statusPublished - May 2018

Fingerprint

Sarcoma
Drug Therapy
Neoadjuvant Therapy
Radiotherapy
Extremities
Therapeutics
Neoplasms

Keywords

  • Chemotherapy, Adjuvant
  • Humans
  • Neoadjuvant Therapy
  • Radiotherapy, Adjuvant
  • Retroperitoneal Neoplasms/therapy
  • Sarcoma/therapy

Cite this

Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. / Almond, L Max; Gronchi, Alessandro; Strauss, Dirk; Jafri, Mariam; Ford, Samuel; Desai, Anant.

In: European Journal of Surgical Oncology, Vol. 44, No. 5, 05.2018, p. 571-579.

Research output: Contribution to journalReview article

Almond, L Max ; Gronchi, Alessandro ; Strauss, Dirk ; Jafri, Mariam ; Ford, Samuel ; Desai, Anant. / Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. In: European Journal of Surgical Oncology. 2018 ; Vol. 44, No. 5. pp. 571-579.
@article{159c87b39c0e47f1b3de5a4b8f920a4b,
title = "Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma",
abstract = "Extended surgery remains the mainstay of treatment in retroperitoneal sarcoma, although conflicting data exist on the benefit of neoadjuvant and adjuvant therapies, particularly with regard to tumour grade and histological type. Experience of radiotherapy and chemotherapy in extremity soft tissue sarcoma can inform treatment strategies, however these data cannot be universally extrapolated to the retroperitoneum where disease biology and anatomical considerations are different. The present review sets a historical context before discussing recent evidence and on-going multi-centre trials in retroperitoneal sarcoma. Promising data on histologically- and molecularly-targeted chemotherapy are discussed and the need for centralisation of retroperitoneal sarcoma services in order to facilitate large international collaborative trials is emphasised.",
keywords = "Chemotherapy, Adjuvant, Humans, Neoadjuvant Therapy, Radiotherapy, Adjuvant, Retroperitoneal Neoplasms/therapy, Sarcoma/therapy",
author = "Almond, {L Max} and Alessandro Gronchi and Dirk Strauss and Mariam Jafri and Samuel Ford and Anant Desai",
note = "Crown Copyright {\circledC} 2018. Published by Elsevier Ltd. All rights reserved.",
year = "2018",
month = "5",
doi = "10.1016/j.ejso.2018.02.001",
language = "English",
volume = "44",
pages = "571--579",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma

AU - Almond, L Max

AU - Gronchi, Alessandro

AU - Strauss, Dirk

AU - Jafri, Mariam

AU - Ford, Samuel

AU - Desai, Anant

N1 - Crown Copyright © 2018. Published by Elsevier Ltd. All rights reserved.

PY - 2018/5

Y1 - 2018/5

N2 - Extended surgery remains the mainstay of treatment in retroperitoneal sarcoma, although conflicting data exist on the benefit of neoadjuvant and adjuvant therapies, particularly with regard to tumour grade and histological type. Experience of radiotherapy and chemotherapy in extremity soft tissue sarcoma can inform treatment strategies, however these data cannot be universally extrapolated to the retroperitoneum where disease biology and anatomical considerations are different. The present review sets a historical context before discussing recent evidence and on-going multi-centre trials in retroperitoneal sarcoma. Promising data on histologically- and molecularly-targeted chemotherapy are discussed and the need for centralisation of retroperitoneal sarcoma services in order to facilitate large international collaborative trials is emphasised.

AB - Extended surgery remains the mainstay of treatment in retroperitoneal sarcoma, although conflicting data exist on the benefit of neoadjuvant and adjuvant therapies, particularly with regard to tumour grade and histological type. Experience of radiotherapy and chemotherapy in extremity soft tissue sarcoma can inform treatment strategies, however these data cannot be universally extrapolated to the retroperitoneum where disease biology and anatomical considerations are different. The present review sets a historical context before discussing recent evidence and on-going multi-centre trials in retroperitoneal sarcoma. Promising data on histologically- and molecularly-targeted chemotherapy are discussed and the need for centralisation of retroperitoneal sarcoma services in order to facilitate large international collaborative trials is emphasised.

KW - Chemotherapy, Adjuvant

KW - Humans

KW - Neoadjuvant Therapy

KW - Radiotherapy, Adjuvant

KW - Retroperitoneal Neoplasms/therapy

KW - Sarcoma/therapy

U2 - 10.1016/j.ejso.2018.02.001

DO - 10.1016/j.ejso.2018.02.001

M3 - Review article

C2 - 29472043

VL - 44

SP - 571

EP - 579

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 5

ER -